Tonix Pharmaceuticals Announces Issuance Of U.S. Patent Covering The Subcutaneous Delivery Of FDA-approved Zembrace Symtouch To Treat Migraines; New Patent Expected To Provide Market Exclusivity Into 2036
Portfolio Pulse from Nabaparna Bhattacharya
Tonix Pharmaceuticals has announced the issuance of a U.S. patent for the subcutaneous delivery of Zembrace Symtouch, an FDA-approved treatment for migraines. This patent is expected to provide market exclusivity until 2036.
September 27, 2024 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals has received a U.S. patent for the subcutaneous delivery of Zembrace Symtouch, which is expected to provide market exclusivity until 2036. This could enhance their competitive position in the migraine treatment market.
The issuance of a patent for the subcutaneous delivery of Zembrace Symtouch provides Tonix Pharmaceuticals with market exclusivity until 2036. This strengthens their competitive edge in the migraine treatment market, potentially boosting their market share and revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100